| Abstract : OBJECTIVE: Anti-tumor necrosis factor alpha (anti-TNF) therapy is a mainstay of treatment in rheumatoid arthritis (RA). The aim of the present study was to test established RA genetic risk factors to determine whether the same alleles also influence the response to anti-TNF therapy. METHODS: A total of 1,283 RA patients receiving etanercept, infliximab, or adalimumab therapy were studied from among an international collaborative consortium of 9 different RA cohorts. The primary end point compared RA patients with a good treatment response according to the European League Against Rheumatism (EULAR) response criteria (n = 505) with RA patients considered to be nonresponders (n = 316). The secondary end point was the change from baseline in the level of disease activity according to the Disease Activity Score in 28 joints (triangle upDAS28). Clinical factors such as age, sex, and concomitant medications were tested as possible correlates of treatment response. Thirty-one single-nucleotide polymorphisms (SNPs) associated with the risk of RA were genotyped and tested for any association with treatment response, using univariate and multivariate logistic regression models. RESULTS: Of the 31 RA-associated risk alleles, a SNP at the PTPRC (also known as CD45) gene locus (rs10919563) was associated with the primary end point, a EULAR good response versus no response (odds ratio [OR] 0.55, P = 0.0001 in the multivariate model). Similar results were obtained using the secondary end point, the triangle upDAS28 (P = 0.0002). There was suggestive evidence of a stronger association in autoantibody-positive patients with RA (OR 0.55, 95% confidence interval [95% CI] 0.39-0.76) as compared with autoantibody-negative patients (OR 0.90, 95% CI 0.41-1.99). CONCLUSION: Statistically significant associations were observed between the response to anti-TNF therapy and an RA risk allele at the PTPRC gene locus. Additional studies will be required to replicate this finding in additional patient collections. |
| Author : Cui J,Saevarsdottir S,Thomson B,Padyukov L,van der Helm-van Mil AH,Nititham J,Hughes LB,de Vries N,Raychaudhuri S,Alfredsson L,Askling J,Wedren S,Ding B,Guiducci C,Wolbink GJ,Crusius JB,van der Horst-Bruinsma IE,Herenius M,Weinblatt ME,Shadick NA,Worthington J,Batliwalla F,Kern M,Morgan AW,Wilson AG,Isaacs JD,Hyrich K,Seldin MF,Moreland LW,Behrens TW,Allaart CF,Criswell LA,Huizinga TW,Tak PP,Bridges SL Jr,Toes RE,Barton A,Klareskog L,Gregersen PK,Karlson EW,Plenge RM, |
